Conference preview: 12th Pharma & Biotech Patent Litigation

27-01-2020

Conference preview: 12th Pharma & Biotech Patent Litigation

Yasonya / Shutterstock.com

Secondary medical use case trends and research exemptions are just two issues set to be discussed at C5’s 12th Pharma & Biotech Patent Litigation meeting, on February 25–26 in Amsterdam.

The event comes at a significant time for European IP, with political uncertainty and the current state of IP proving a series of challenges for pharmaceutical and biotech companies conducting business in Europe.

Attendees at C5’s 12th Pharma & Biotech Patent Litigation will obtain clarification on a raft of matters, and develop an understanding of their consequential impact on patent litigation strategies.

Key takeaways for the 2020 event include:

  • Developing best practice approaches for new Board of Appeal rules at the European Patent Office;
  • Determining which research exemptions are available in Europe and the US; and
  • Formulating strategies relative to the latest secondary medical use case trends.

A faculty of in-house counsel and regulatory executives will share solutions and practical approaches to the most pressing IP challenges impacting the life sciences industry.

LSIPR readers will receive a 10% discount when registering with this code: D10-630-630CX02 at https://www.c5-online.com/pharmalitigation

 

For more information on the event, click here.

pharma-biotech.jpg

C5, medical use, biotech, patent litigation, European IP, Board of Appeal, EPO, in-house counsel, life sciences, pharmaceutical industry

LSIPR